cilostazol has been researched along with Anterior Circulation Transient Ischemic Attack in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term treatment with the combination of cilostazol with aspirin or clopidogrel showed a lower risk of stroke recurrence compared to aspirin or clopidogrel alone after high-risk noncardioembolic ischemic stroke in a randomized trial." | 9.51 | Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis. ( Hoshino, H; Ihara, M; Kimura, K; Kitagawa, K; Koga, M; Minematsu, K; Miwa, K; Omae, K; Suda, Y; Toru, S; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2022) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 7.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "Long-term treatment with the combination of cilostazol with aspirin or clopidogrel showed a lower risk of stroke recurrence compared to aspirin or clopidogrel alone after high-risk noncardioembolic ischemic stroke in a randomized trial." | 5.51 | Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis. ( Hoshino, H; Ihara, M; Kimura, K; Kitagawa, K; Koga, M; Minematsu, K; Miwa, K; Omae, K; Suda, Y; Toru, S; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2022) |
| " Cilostazol proved to be the most efficacious in reducing stroke recurrence and the risk of bleeding (RR = 0." | 5.22 | Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials. ( Bálint, A; El Abdallaoui, OEA; Komócsi, A; Kupó, P; Szapáry, L; Szapáry, LB; Tornyos, D, 2022) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Patients who participated in the Acute Aspirin Plus Cilostazol Dual Therapy for Non-cardiogenic Stroke Patients Within 48 Hours of Symptom Onset (ADS) trial were included in this study." | 4.31 | Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis. ( Aoki, J; Fujimoto, S; Kimura, K; Matsuzono, K; Ozawa, T, 2023) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 3.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "In the past, transient ischemic attack (TIA) was defined as any sudden, focal cerebral ischemic event with neurological deficit lasting <24 hours." | 2.46 | [New clinical concept and therapeutic strategy for TIA]. ( Urabe, T, 2010) |
| "Cilostazol is known to be a specific type III phosphodiesterase inhibitor, which promotes increased intracellular cAMP levels." | 1.36 | Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia. ( Hong, KW; Kim, CD; Lee, DH; Lee, HR; Lee, JH; Lee, JS; Lee, SJ; Lee, WS; Park, SY; Rhim, BY; Shin, HK, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 11 (47.83) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Toyoda, K | 1 |
| Omae, K | 1 |
| Hoshino, H | 1 |
| Uchiyama, S | 1 |
| Kimura, K | 2 |
| Miwa, K | 1 |
| Minematsu, K | 1 |
| Yamaguchi, K | 1 |
| Suda, Y | 1 |
| Toru, S | 1 |
| Kitagawa, K | 1 |
| Ihara, M | 1 |
| Koga, M | 1 |
| Yamaguchi, T | 1 |
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Tornyos, D | 1 |
| Komócsi, A | 1 |
| Bálint, A | 1 |
| Kupó, P | 1 |
| El Abdallaoui, OEA | 1 |
| Szapáry, L | 1 |
| Szapáry, LB | 1 |
| Jung, SJ | 1 |
| Shim, SR | 1 |
| Kim, BJ | 2 |
| Jung, JM | 1 |
| Ozawa, T | 1 |
| Fujimoto, S | 1 |
| Aoki, J | 1 |
| Matsuzono, K | 1 |
| Kono, K | 1 |
| Shintani, A | 1 |
| Yoshimura, R | 1 |
| Okada, H | 1 |
| Tanaka, Y | 2 |
| Fujimoto, T | 1 |
| Tomura, N | 1 |
| Terada, T | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Wang, W | 1 |
| Zhang, L | 1 |
| Liu, W | 1 |
| Zhu, Q | 1 |
| Lan, Q | 1 |
| Zhao, J | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Miyamoto, N | 1 |
| Tanaka, R | 2 |
| Shimosawa, T | 1 |
| Yatomi, Y | 1 |
| Fujita, T | 1 |
| Hattori, N | 2 |
| Urabe, T | 3 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Shin, HK | 4 |
| Lee, HR | 1 |
| Lee, DH | 1 |
| Hong, KW | 4 |
| Lee, JH | 4 |
| Park, SY | 3 |
| Lee, SJ | 1 |
| Lee, JS | 2 |
| Lee, WS | 3 |
| Rhim, BY | 1 |
| Kim, CD | 3 |
| Liu, M | 1 |
| Easton, JD | 1 |
| Yamamoto, Y | 1 |
| Ohara, T | 1 |
| Nagakane, Y | 1 |
| Tanaka, E | 1 |
| Morii, F | 1 |
| Koizumi, T | 1 |
| Kasahara, Y | 1 |
| Nakagomi, T | 1 |
| Matsuyama, T | 1 |
| Stern, D | 1 |
| Taguchi, A | 1 |
| Heo, SH | 1 |
| Hwang, KJ | 1 |
| Kim, JH | 1 |
| Chang, DI | 1 |
| Liao, JK | 1 |
| Ohara, M | 1 |
| Nagara, Y | 1 |
| Shida, N | 1 |
| Yamashita, Y | 1 |
| Choi, JM | 1 |
| Kim, KY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for cilostazol and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials.
Topics: Aspirin; Cilostazol; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic S | 2022 |
Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis.
Topics: Cilostazol; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Network Meta-Analysis; Pl | 2022 |
Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis.
Topics: Asian People; Brain Ischemia; Cilostazol; Humans; Ischemic Attack, Transient; Network Meta-Analysis; | 2016 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clop | 2011 |
[New clinical concept and therapeutic strategy for TIA].
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diffusion Magnetic Resonance Imaging; Humans; Ischemic Attac | 2010 |
[Concept of branch atheromatous disease (BAD) and its clinical significance].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Edaravone; Humans; | 2010 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.
Topics: Cerebrovascular Disorders; Chronic Disease; Cilostazol; Clinical Trials as Topic; Humans; Ischemic A | 2008 |
1 trial available for cilostazol and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis.
Topics: Cilostazol; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhi | 2022 |
12 other studies available for cilostazol and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis.
Topics: Blood Pressure; Cilostazol; Humans; Ischemic Attack, Transient; Ischemic Stroke; Recurrence; Stroke | 2023 |
Triple antiplatelet therapy with addition of cilostazol to aspirin and clopidogrel for Y-stent-assisted coil embolization of cerebral aneurysms.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; | 2013 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Protein kinase A-dependent suppression of reactive oxygen species in transient focal ischemia in adrenomedullin-deficient mice.
Topics: Adrenomedullin; Animals; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleo | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia.
Topics: Adult Stem Cells; Animals; CA1 Region, Hippocampal; Cell Death; Cell Proliferation; Cilostazol; Dise | 2010 |
Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia.
Topics: Animals; Brain Infarction; Bromodeoxyuridine; Cell Count; Cerebral Ventricles; Cilostazol; CREB-Bind | 2010 |
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry; | 2012 |
Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients.
Topics: Adult; Aged; Analysis of Variance; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholester | 2013 |
Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis Inducing Factor; CD11 Antigens; Cilostaz | 2007 |
[Marked effectiveness of cilostazol in a case of hemodynamic TIA].
Topics: Bradycardia; Cilostazol; Diagnostic Imaging; Humans; Ischemic Attack, Transient; Male; Middle Aged; | 2007 |
Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain Infarction; Cilostazol; Cyc | 2002 |